The country's central bank said that it would also allow "qualified" firms to participate in the initiative.

83% of participants on tecovirimat achieved clinical resolution, compared to 84% on placebo, which was not significantly different. Pain reduction was similar in both groups, with tecovirimat users reporting a 3.2-point decrease and placebo users a 3.1-point decrease.

PALO ALTO, Calif. and LEXINGTON, Mass., March 12, 2025 ( GLOBE NEWSWIRE ) -- Kalaris Therapeutics, Inc. ( "Kalaris" ) , a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent diseases of the retina, and AlloVir, Inc.

Lyft's LYFT short percent of float has fallen 12.37% since its last report. The company recently reported that it has 43.25 million shares sold short, which is 12.4% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.05 days to cover their ...

XIAMEN, China, March 12, 2025 ( GLOBE NEWSWIRE ) -- Blue Hat Interactive Entertainment Technology ( "Blue Hat" or the "Company" ) BHAT, a Cayman Islands company, reported that it expects to implement a 1-for-100 reverse stock split on its ordinary shares effective Monday, March 17, 2025, with ...

Successfully Completed Lab and Field Demonstrations Validating Effectiveness of NextNav's 5G PRS-based PNT solution ...

RICHMOND HILL, ON, March 12, 2025 /CNW/ - After 57 years of inspiring musicians and creating memorable experiences, Cosmo Music, Canada's largest music store, announces the closure of its operations.

Revenue In Line With Expectations. Continued Progress to Enhance Profitability and Drive Margin Expansion Revenue In Line With Expectations. Continued Progress to Enhance Profitability and Drive Margin Expansion ...

ROMEOVILLE, Ill., March 12, 2025 ( GLOBE NEWSWIRE ) -- Solésence, Inc. ( OTCQB: NANX ) , a leader in scientifically-driven health care solutions across beauty and life science categories, today announced the launch of its new investor relations website.

PURCHASE N.Y., March 12, 2025 ( GLOBE NEWSWIRE ) -- Cognition Therapeutics, Inc. ( Nasdaq: CGTX ) , a clinical stage company developing product candidates that treat neurodegenerative disorders, ( the "Company" or "Cognition" ) , was notified by the Nasdaq Stock Market LLC ( "Nasdaq" ) on ...